Late-stage cancer and poor outcomes for patients may occur as a result of low screening numbers during the COVID-19 pandemic.
Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.
An integrated review highlights the barriers standing between diverse LGBTQ populations and cancer screenings.
Seventeen years of data indicate that HPV-related cervical cancer incidence is declining, but other tumors related to the virus persist.
Recommendations published in JAMA are set to change colorectal cancer screening guidance for all individuals in the United States.
In his "Letter to the Readers", co-editor-in-chief of the journal ONCOLOGY Howard S. Hochster, MD, reviews the utility of next-generation sequencing in pancreatic ductal adenocarcinoma.
CancerNetwork® reports on updates in prevention and earlier diagnosis of colorectal, breast, and other cancers.
A novel imaging technology was cleared by the FDA to detect polyps with neoplastic potential during conduct of colonoscopy that aligns with pathological assessment with greater than 90% predictive ability.
The liquid biopsy assay RaDaR has been given a breakthrough device designation for use in the detection of minimal residual disease in early-stage cancers.
Investigators suggest that results of a study may help to identify concerns of individuals undergoing panel testing and ways to support their needs.